

	Introduction	Cas
•	Sarcoidosis is a rare systemic inflammatory disease characterized by non-caseating granulomas.	 A on wa b
	Most patients are asymptomatic but hepatic sarcoidosis can progress to portal hypertension which can be cirrhotic or non-cirrhotic. Definitive diagnosis is made by liver biopsy. ¹	Co pr 2 fu
•	This is a case of hepatic sarcoidosis presenting with elevation in alkaline phosphatase (ALP) which improved with treatment.	an an Li pc
Fi	gure 1. Ultrasound of the abdomen showing hepatic steatosis.	an ne m
	Left Liver	sta ch gr Th an se in
		Table

Figure 2. Magnetic resonance cholangiopancreatography showing periportal lymphadenopathy.





Abdominal sarcoidosis including hepatic and portal lymphadenopathy as a primary manifestation in a case of systemic sarcoidosis Saatchi Kuwelker, MD, Farah Ladak, MD, Eugenia Tsai, MD The University of Texas Health Science Center at San Antonio

se

Lab

Alkal

Alanir

Aspar

Total

INR

50 year-old man presented with three months of worsening dyspnea n exertion and dysphagia to liquids and solids. On arrival, the patient as tachycardic, tachypneic and hypoxemic. Laboratory values during ospital stay are shown in Table 1.

computed tomography of the chest showed a small apical neumothorax and reticular opacities with bronchiectasis. Figured 1 and depict findings of ultrasound and MRCP respectively. Work-up for ingal, autoimmune and infectious etiologies was negative except for an nti-mitochondrial antibody of 29 units and anti-smooth muscle ntibody of 30 units.

iver biopsy revealed granulomatous portal and lobular inflammation, ortal lymphocytic inflammation with ductitis, focal interface hepatitis nd focal bridging fibrosis (Figure 3 and 4). Lung biopsy showed nonecrotizing granulomas that initially was thought to be due to atypical nycobacteria and not sarcoidosis. The patient was not immediately tarted on steroids thereafter. Ursodiol was initiated to help with holestasis. Biopsy of portal lymph nodes confirmed non-caseating ranulomas.

he patient was then diagnosed with systemic sarcoidosis with hepatic nd pulmonary involvement. He was started on steroids in the outpatient etting in conjunction with ursodiol. Liver enzymes subsequently nproved at the end of hospital stay as shown in Table 1.

e1. Progression of Liver function tests during course of illness.

value	Day 1	Day 15	Day 30
ne phosphatase	458	232	188
ne transaminase	113	40	59
tate transaminase	110	56	82
oilirubin	0.6	0.6	0.7
	1	1	1

Discussion

Figure 3. H &E stained images of a large lobular focus of non-caseating granulomatous inflammation with interdigitating hyaline fibrosis in 200x magnification (black arrow). Hepatic parenchyma without steatosis and a small focus of lymphocytic inflammation (red arrow)

Figure 4. H&E stain of portal tract expanded by a poorly formed granuloma with a multinucleated giant cell in 400x magnification (black arrow). The remaining portal tract shows a lymphohistiocytic infiltrate with infiltration and damage of the bile duct by lymphocytes.



1. Ryland K. L. (2020). Hepatic Sarcoidosis: Incidence, Monitoring, and Treatment. Clinical liver disease, 16(5), 208–211. https://doi.org/10.1002/cld.1002

2. Tadros M, Forouhar F, Wu GY. Hepatic Sarcoidosis. J Clin Transl Hepatol. 2013 Dec;1(2):87-93. doi: 10.14218/JCTH.2013.00016. Epub 2013 Dec 15. PMID: 26357609; PMCID: PMC4521279.

Sarcoidosis should be among one of the differentials in patients presenting with predominant ALP elevation in the absence of bilirubin elevation and concomitant lung manifestations.

• A liver biopsy is essential for diagnosing hepatic sarcoidosis and to rule out other similar pathologies like primary biliary cholangitis and primary sclerosing cholangitis.²

Ursodiol in conjunction with steroids can help improve liver enzyme elevations seen in hepatic sarcoidosis.^{1,2}

References